Joseph Bresee, MD
Director, Partnership for Influenza Vaccine Introduction, Task Force for Global Health, and Associate Director for Global Health Affairs, Influenza Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention
Dr. Bresee leads the PIVI team and has more than twenty years of experience working in influenza and vaccines, having started his public health career at the CDC as an EIS officer in the Influenza Branch in 1993. From 1995 to 2005, Dr. Bresee worked at CDC on viral diseases, with a focus on research and public health activities related to rotavirus disease and rotavirus vaccines to help ensure that rotavirus vaccines were available for children in both the U.S. as well as those living in developing countries. From 2005 – 2017, Dr. Bresee led the Epidemiology and Prevention Branch of the CDC’s Influenza Division. The Branch is responsible for conducting influenza surveillance, working to understand influenza disease burden, helping to derive appropriate vaccine and antiviral use policies to prevent seasonal influenza, detecting and preventing avian influenza and pandemic influenza, and providing technical expertise to global public health partners.
In 2017, Dr. Bresee was named Associate Director for Global Health Affairs in CDC’s Influenza Division. He brings his expertise in influenza and the expertise and resources of his team to PIVI, spearheading the relationships with country partners. He also regularly participates in national and international meetings and technical groups on immunization and influenza. Dr. Bresee has authored more than 250 peer-reviewed papers and textbook chapters.
Mark McKinlay, PhD
Director, Center for Vaccine Equity, The Task Force for Global Health
Mark McKinlay, PhD, is director for the Center for Vaccine Equity (CVE), a program of The Task Force for Global Health. In this role, Dr. McKinlay oversees The Task Force’s work to increase access to vaccines for cholera and influenza in developing countries. He also guides The Task Force’s work to help eradicate polio.
Prior to joining The Task Force, Dr. McKinlay was co-founder, chief scientific officer, and senior vice president for research and development of TetraLogic Pharmaceuticals based in Malvern, Pa. At TetraLogic, Mark led the team that discovered and developed a novel, best-in-class drug targeting the inhibitors of apoptotic proteins for the treatment of cancer.
Prior to TetraLogic, Dr. McKinlay co-founded ViroPharma Inc. and served as vice president of research and development. While there, he led the development of an antipicornavirus agent that culminated in the first clinical demonstration that an antiviral can affect the duration and severity of the common cold.
For nearly 15 years, Dr. McKinlay served in varying roles, including senior director of virology and oncopharmacology in the research group, at Sterling Drug. There he discovered a novel class of antipicornavirus agents and advanced three of these agents into clinical trials. While at Sterling Drug he also demonstrated that oral delivery of an antipicornavirus agent was effective in treating poliovirus infections in mice.
Dr. McKinlay holds master’s and doctoral degrees from Rensselaer Polytechnic Institute, and completed a postdoctoral research fellowship in virology at The Johns Hopkins University School of Hygiene and Public Health. He received his undergraduate degree from Union College.
Jane Seward, MBBS, MPH
Independent Consultant, Partnership for Influenza Vaccine Introduction
The PIVI team also includes the following individuals from The Task Force and the CDC:
Eduardo Azziz-Baumgartner, MD, MPH
International Epidemiology and Research Team Lead, Influenza Division, US Centers for Disease Control and Prevention
Project Support Specialist, Center for Vaccine Equity, The Task Force for Global Health
Associate Director, Development and Partnerships, Center for Vaccine Equity, The Task Force for Global Health
Pamela Ching, MS, SD, RD/LD
Senior Supervisory Epidemiologist and Research Coordinator, AFRO Region, International Epidemiology and Research Team, Epidemiology and Prevention Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevemtion
Susan Chu, PhD, MSPH
Senior Epidemiologist, Center for Global Health, Global Immunization Division, US Centers for Disease Control and Prevention
Malembe Ebama, DrPH, MPH
Epidemiologist, Center for Vaccine Equity, The Task Force for Global Health
Alan Hinman, MD, MPH
Senior Advisor, Center for Vaccine Equity, The Task Force for Global Health
Terri Hyde, MD, MPH
Team Lead, Vaccine Introduction Global Immunization Division, Immunization Systems Branch, US Centers for Disease Control and Prevention
Deputy Director, Center for Vaccine Equity, The Task Force for Global Health
Katie Lafond, MPH
Epidemiologist, US Centers for Disease Control and Prevention
Epidemiologist, Extramural Activities Group, Influenza Division, US Centers for Disease Control and Prevention
Ann Moen, MPA
Associate Director, Extramural Programs, Influenza Division, US Centers for Disease Control and Prevention